Glycolysis

Glycolysis
Thomas Shafee · CC BY 4.0 · source
Name	Glycolysis
Organism	Universal

Glycolysis is a central metabolic pathway that converts glucose into pyruvate, generating adenosine triphosphate (ATP) and reducing equivalents in the form of nicotinamide adenine dinucleotide (NADH). The pathway is conserved across diverse taxa and features in cellular processes studied by researchers associated with institutions like Max Planck Society, Johns Hopkins University, Harvard University, University of Cambridge, and Stanford University. Historical figures connected to its elucidation include Otto Warburg, Arthur Harden, Hans Krebs, Emil Fischer, and Louis Pasteur.

Overview

Glycolysis operates in the cytosol of eukaryotic cells and in the cytoplasm of prokaryotes, bridging research contexts involving Cambridge University Press publications, reports from World Health Organization, and reviews in journals such as Nature, Science, Cell, Proceedings of the National Academy of Sciences, and The Lancet. Key molecules in the pathway interact with enzymes studied by laboratories at Massachusetts Institute of Technology, University of Oxford, ETH Zurich, University of Tokyo, and Karolinska Institutet. Experimental techniques from facilities like European Molecular Biology Laboratory and Cold Spring Harbor Laboratory have refined knowledge about intermediates tied to awards such as the Nobel Prize in Physiology or Medicine.

Pathway and Biochemical Steps

The ten-step pathway begins with phosphorylation of glucose by hexokinase or glucokinase, enzymes discussed in reviews from Royal Society of Chemistry and textbooks published by Oxford University Press. Steps proceed through glucose-6-phosphate and fructose-6-phosphate, catalyzed by phosphoglucose isomerase and phosphofructokinase, then through aldolase and triosephosphate isomerase to yield glyceraldehyde-3-phosphate. Subsequent enzymes—glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase, and pyruvate kinase—complete conversion to pyruvate while producing ATP and NADH. Structural studies from groups at European Synchrotron Radiation Facility, Riken, and Los Alamos National Laboratory have resolved active sites similar to those cataloged by Protein Data Bank. Glycolytic intermediates intersect with pathways described in monographs from Cambridge University Press such as the pentose phosphate pathway, gluconeogenesis, and the citric acid cycle investigated by Hans Krebs and laboratories at Max Planck Institute for Biochemistry.

Regulation and Control

Regulatory control involves allosteric effectors and covalent modification of enzymes like phosphofructokinase and pyruvate kinase; regulatory paradigms appear in policy briefs from National Institutes of Health, grant reports from Wellcome Trust, and curricula at University of California, Berkeley. Hormonal regulation by insulin and glucagon, investigated by teams at Imperial College London and Yale University, modulates flux through hexokinase and phosphofructokinase. Cellular energy charge sensed by adenylate kinase and AMP-activated protein kinase links to signaling pathways characterized in studies from Broad Institute and Salk Institute. Metabolic control analysis techniques from University of Manchester and University of Wisconsin–Madison quantify control coefficients; computational frameworks implemented at European Bioinformatics Institute integrate omics datasets from Human Genome Project and initiatives like ENCODE.

Physiological Roles and Variations

Glycolytic flux varies among tissues—liver, muscle, brain, red blood cells—and in specialized cells studied at clinical centers including Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. Muscle glycolysis during exercise is central to findings reported by International Olympic Committee-affiliated researchers, while brain energetics involves collaborations with institutions like National Institute of Mental Health and Massachusetts General Hospital. Microbial glycolysis in species such as Escherichia coli, Saccharomyces cerevisiae, and Mycobacterium tuberculosis underpins biotechnology applications promoted by Biotechnology and Biological Sciences Research Council and companies listed on exchanges like NASDAQ and London Stock Exchange. Variants include the Entner–Doudoroff pathway characterized in classical studies from University of California, San Diego and the 3-hydroxypropionate bicycle described by teams at California Institute of Technology.

Clinical Significance and Disorders

Aberrations in glycolysis contribute to conditions investigated by clinical researchers at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center; tumor cells often exhibit altered glycolytic metabolism consistent with observations linked to Otto Warburg. Genetic deficiencies affecting glycolytic enzymes cause diseases cataloged by National Organization for Rare Disorders and treated in protocols from American College of Physicians and European Society of Cardiology. Therapeutic strategies targeting glycolytic enzymes are under development by biotechnology firms and consortia funded by Bill & Melinda Gates Foundation and European Commission programs; diagnostics leverage metabolomic platforms established by Thermo Fisher Scientific and Agilent Technologies. Clinical trials registered with ClinicalTrials.gov assess inhibitors and modulators with relevance to metabolic syndrome, cancer, ischemia, and inherited enzyme defects.

Category:Metabolism